LYPLA1 and neoplasm: We have previously shown the presence of antigen (HapT1) specific T cells in HapT1 tumours, 6 days post implantation, demonstrated by the ability to expand tumour infiltrating lymphocytes for a cell line-matched ex vivo cytotoxicity assay (19).